Analysts expect that BioTelemetry Inc (NASDAQ:BEAT) will post earnings per share (EPS) of $0.45 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for BioTelemetry’s earnings. The lowest EPS estimate is $0.44 and the highest is $0.46. BioTelemetry posted earnings per share of $0.46 during the same quarter last year, which would indicate a negative year-over-year growth rate of 2.2%. The company is expected to announce its next earnings report on Wednesday, July 24th.
On average, analysts expect that BioTelemetry will report full-year earnings of $1.90 per share for the current year, with EPS estimates ranging from $1.81 to $2.01. For the next financial year, analysts expect that the business will post earnings of $2.08 per share, with EPS estimates ranging from $1.95 to $2.20. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for BioTelemetry.
BioTelemetry (NASDAQ:BEAT) last released its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.42 earnings per share for the quarter, hitting the consensus estimate of $0.42. BioTelemetry had a net margin of 11.86% and a return on equity of 23.36%. The business had revenue of $103.98 million for the quarter, compared to analysts’ expectations of $104.17 million. During the same period in the previous year, the company earned $0.39 earnings per share. The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year.
BioTelemetry stock traded down $1.62 during midday trading on Wednesday, hitting $46.88. 17,081 shares of the stock were exchanged, compared to its average volume of 364,088. BioTelemetry has a 52-week low of $43.30 and a 52-week high of $80.92. The company has a market capitalization of $1.62 billion, a PE ratio of 24.13 and a beta of 1.42. The stock’s 50-day simple moving average is $49.22. The company has a quick ratio of 1.84, a current ratio of 1.99 and a debt-to-equity ratio of 0.57.
In other BioTelemetry news, Director Kirk E. Gorman sold 5,518 shares of the business’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $54.37, for a total value of $300,013.66. Following the transaction, the director now directly owns 178,833 shares in the company, valued at $9,723,150.21. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.50% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. raised its position in shares of BioTelemetry by 72.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,895 shares of the medical research company’s stock valued at $114,000 after purchasing an additional 794 shares during the period. National Asset Management Inc. bought a new stake in BioTelemetry during the 1st quarter worth approximately $218,000. Logan Capital Management Inc. increased its holdings in BioTelemetry by 3.4% during the 4th quarter. Logan Capital Management Inc. now owns 54,289 shares of the medical research company’s stock worth $3,242,000 after acquiring an additional 1,765 shares during the period. Brinker Capital Inc. bought a new stake in BioTelemetry during the 1st quarter worth approximately $617,000. Finally, BlackRock Inc. increased its holdings in BioTelemetry by 2.7% during the 4th quarter. BlackRock Inc. now owns 5,092,773 shares of the medical research company’s stock worth $304,141,000 after acquiring an additional 134,956 shares during the period. 90.66% of the stock is currently owned by institutional investors.
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.
Recommended Story: Day Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.